Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05669417
Other study ID # T-21-118
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date August 1, 2022
Est. completion date January 31, 2025

Study information

Verified date January 2024
Source HagaZiekenhuis
Contact Jeroen Ludikhuize, MD, PhD, MSc
Phone +31702100000
Email j.ludikhuize@hagaziekenhuis.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-operative atrial fibrillation (POAF) is commonly observed in patients post cardiac surgery without a previous history of atrial fibrillation (AF) or other arrythmias. It's associated with significant postoperative complications including infection, bleeding reoperation, increased hospital length of stay (LOHS) and mortality. Magnesium has been identified as a potentially interesting compound with easy access and low toxicity. Hypomagnesemia has been observed frequently immediately after cardiac surgery. Both reduction of abnormal atomicity of atrial myocardium and prolongation of the atrial refractory period caused by administration of magnesium may prevent AF. The POMPAE trial will analyse the effectiveness of MgSO4 versus placebo (double blind randomized trial) in the prevention of POAF after cardiac surgery.


Description:

Post-operative atrial fibrillation (POAF) is commonly observed in patients post cardiac surgery without a previous history of atrial fibrillation (AF) or other arrythmias. (1) Within this population, AF is considered to be multifactorial in origin (2) but associated with significant postoperative complications including infection, bleeding reoperation, increased hospital length of stay (LOHS) and mortality. (3,4) Multiple interventions have been tried before including anti-arrhythmic drugs (amiodaron, verapamil, sotalol) and rate reducing agents like beta-blockers. (5-7) Although encouraging results have been found with different regimes, adaptation in clinical practice has been hampered by toxicity (amiodarone) and therapeutic index. Magnesium has been identified as a potentially interesting compound with easy access and low toxicity; besides, hypomagnesemia has been observed frequently immediately after cardiac surgery. (8,9) Both reduction of abnormal activity of atrial myocardium and prolongation of the atrial refractory period caused by administration of magnesium may prevent AF. (10) Magnesium metabolism has identified that less then 1% of the total magnesium content is intravascular and serum levels don't always correlate with intracellular concentrations. (11) Hypomagnesaemia is associated with increased ventricular tachycardia and atrial fibrillation which is likely caused by a reduction in membrane triphosphate (ATP) activity. This results in reduced membrane stabilization due to a reduction in intracellular potassium compared to extracellular concentrations thus increasing electrical excitability. (12) Also measuring the intracellular concentration is difficult and especially in a routine fashion as loading tests followed by 24 hour urine analysis (13) and energy-dispersive X-ray analysis are not available. (14) Administration of magnesium sulphate does however correlate to higher intracellular magnesium concentration compared to placebo. (14) Several studies in different populations have shown a reduction in arrhythmias post magnesium supplementation. (15) Previous studies suggest that magnesium administration after cardiac surgery is effective in reducing the incidence of AF. (16) However, uncertainty remains regarding optimal dose/blood levels, duration and method of magnesium administration. (17) In a recent study using a protocol for administration of magnesium aiming for blood levels between 1.5 and 2.0 mmol/L an absolute reduction of POAF of 15.1% (OR 0.49, 95% CI 0.27-0.92) was demonstrated. (18) Based on this study, we designed the POMPAE trial (Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated). The POMPAE trial is a double blinded randomized clinical trial to investigate the efficacy of magnesium supplementation and the reduction of POAF.


Recruitment information / eligibility

Status Recruiting
Enrollment 530
Est. completion date January 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Elective cardiac surgery (valve surgery and/or CABG) - 18 years and above - Mentally competent Exclusion Criteria: - History of atrial fibrillation (AF) or atrial flutter. - Concomitant rhythm associated procedures (MAZE (surgical ablation)/PVI (pulmonary vein isolation)). - Pre-existing severe renal impairment (eGFR<30 ml/min). - Pre-existing 3rd degree heart block without pacemaker presence.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Magnesium sulfate
Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.

Locations

Country Name City State
Netherlands HagaZiekenhuis The Hague South-Holland

Sponsors (1)

Lead Sponsor Collaborator
HagaZiekenhuis

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of new-onset postoperative atrial fibrillation (POAF) New-onset POAF over a period of 5 minutes or longer First seven postoperative days
Secondary 28-day postoperative atrial fibrillation (POAF) post-surgery The incidence of POAF in the first 28 days post surgery diagnosed with ECG 28 days post surgery
Secondary Duration of POAF and peak heart rate recorded The duration of POAF as recorded in the patient chart including the peak heart rate (in bpm) 28 days post surgery
Secondary Length of hospital stay The total length of hospital stay from day of admission until hospital discharge irrespective of outcome (diseased, home, rehab etc) Total duration of hospital stay
Secondary Length of ICU stay The total length of ICU stay from the moment post surgery until discharge to the ward. Possible readmissions are not part of this outcome parameter Total length of ICU stay after surgery
Secondary Duration of mechanical ventilation The total length of invasive mechanical ventilation from the moment post surgery until discharge to the ward. Possible readmissions are not part of this outcome parameter Total length of mechanical ventilation during ICU stay after surgery
Secondary Duration of inotropic and/or vasopressor support The duration of inotropic and/or vasopressor support from the start of anaesthesia until discharge to the ward. Possible readmissions are not part of this outcome parameter Total length of inotropic/vasopressor support from induction of anaesthesia until ICU discharge
Secondary Combined outcome including 28-day post-surgery mortality, stroke, pulmonary embolism, delirium (requiring any form of anti-psychotic medication and/or infection requiring antibiotics The incidence of the combined outcome of 28-day mortality (outcome 2), the incidence of stroke as per advise neurology department, pulmonary embolism (Ct diagnosis), delirium requiring antipsychotics and/or the use of antibiotics apart from surgical/ICU prophylaxis. 28 days post surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Recruiting NCT04870424 - Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Phase 3
Completed NCT05818592 - Screening for Atrial Fibrillation With Self Pulse Monitoring N/A
Active, not recruiting NCT05780320 - A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery
Active, not recruiting NCT03866148 - Obstructive Sleep Apnoea and Cardiac Arrhythmias N/A
Withdrawn NCT05656170 - Stellate Ganglion to Prevent Atrial Fibrillation N/A
Active, not recruiting NCT05255224 - PARADISE: Predicting AF After Cardiac Surgery
Recruiting NCT04528511 - BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
Recruiting NCT04857268 - Diagnostic Validation of Wearable ECG Monitoring Patch, ATP-C120 N/A
Completed NCT04118270 - Shared Decision-Making: AFib 2gether Mobile App N/A
Active, not recruiting NCT03345615 - Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation N/A
Not yet recruiting NCT05841056 - Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial Phase 3
Recruiting NCT06275503 - STROKESTOP III - Optimized Method for Atrial Fibrillation Screening N/A
Recruiting NCT05149820 - Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments Phase 4
Completed NCT03221777 - Atrial Fibrillation Occurring Transiently With Stress (AFOTS)
Not yet recruiting NCT03991754 - Prevention of New Onset AF After TAVI (PAF-TAVI Trial) Phase 3
Completed NCT03118518 - STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation N/A
Completed NCT03552588 - High Sensitivity Estimate of the Incidence of Atrial Fibrillation Occurring Transiently With Stress (AFOTS Incidence Study)
Recruiting NCT05444335 - Screening for Atrial Fibrillation in Elderly Women Older Than 70 Years N/A
Not yet recruiting NCT06458829 - Promoting Atrial Fibrillation Screening in Primary Care N/A